Coherus BioSciences (CHRS) Reports Q3 EPS of $1.67
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $0.85 +4.94%
Revenue Growth %: +37.8%
Financial Fact:
Basic net income/(loss) per share: 0.15
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +37.8%
Financial Fact:
Basic net income/(loss) per share: 0.15
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of $1.67, versus ($1.86) reported last year. Revenue for the quarter came in at $162.8 million, versus $7.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Assumes Coherus Biosciences (CHRS) at Buy
- Datadog stock tumbles 19% despite earnings beat
- Walmart stock climbs on AI shopping tool expansion
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
